MARKET

QTTB

QTTB

Q32 BIO INC
NASDAQ
1.870
+0.020
+1.08%
After Hours: 1.923 +0.053 +2.81% 19:28 04/25 EDT
OPEN
1.920
PREV CLOSE
1.850
HIGH
1.995
LOW
1.820
VOLUME
70.79K
TURNOVER
--
52 WEEK HIGH
53.79
52 WEEK LOW
1.380
MARKET CAP
22.78M
P/E (TTM)
-0.3652
1D
5D
1M
3M
1Y
5Y
1D
Q32 Bio Board Member Mark Iwicki Resigns
TipRanks · 2d ago
Q32 BIO INC - IWICKI RESIGNS TO FOCUS ON CEO ROLE AT INHIBIKASE THERAPEUTICS
Reuters · 2d ago
Weekly Report: what happened at QTTB last week (0414-0418)?
Weekly Report · 6d ago
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
TipRanks · 04/18 13:57
Q32 Bio doses first patient in both parts of SIGNAL-AA trial
TipRanks · 04/16 11:08
Q32 BIO INC - EXPECTS SIGNAL-AA PART B DATA IN 1H'26
Reuters · 04/16 10:59
Weekly Report: what happened at QTTB last week (0407-0411)?
Weekly Report · 04/14 09:17
Q32 BIO FILES FOR MIXED SHELF OF UP TO $200 MLN - SEC FILING
Reuters · 04/11 21:47
More
About QTTB
More
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Recently
Symbol
Price
%Change

Webull offers Q32 Bio Inc stock information, including NASDAQ: QTTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QTTB stock methods without spending real money on the virtual paper trading platform.